Peptide Initiative

Peptides · Peptide comparison

Gonadorelin (GnRH) vs Leuprolide

The master hormone that controls your reproductive system and fertility

A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeGonadorelin (GnRH)100–100 mcgLeuprolide1–1 mg
FrequencyGonadorelin (GnRH)Once dailyLeuprolideOnce daily
AdministrationGonadorelin (GnRH)Subcutaneous injectionLeuprolideSubcutaneous injection (daily)
Cycle lengthGonadorelin (GnRH)Ongoing/indefiniteLeuprolideOngoing/indefinite
Onset speedGonadorelin (GnRH)Moderate (1-2 weeks)LeuprolideModerate (1-2 weeks)
Evidence levelGonadorelin (GnRH)Moderate human trials (Phase 1-2)LeuprolideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Reproductive Health

Gonadorelin (GnRH)95%
LeuprolideNo recorded rating

Hormone Balance

Gonadorelin (GnRH)90%
LeuprolideNo recorded rating

Ovulation Support

Gonadorelin (GnRH)88%
LeuprolideNo recorded rating

Cancer Management

Gonadorelin (GnRH)No recorded rating
Leuprolide94%

Endometriosis & Fibroid Relief

Gonadorelin (GnRH)No recorded rating
Leuprolide90%

Hormone Control

Gonadorelin (GnRH)No recorded rating
Leuprolide87%

Technical data

Compound specifications

Gonadorelin (GnRH)

Molecular formula
C55H75N17O13
Molecular weight
1182.3
Half-life
2-4 minutes
Bioavailability
Varies by route: ~5-20% (intranasal), 100% (IV/IM injections)
CAS number
34973-08-5

Leuprolide

Molecular formula
C59H84N16O12
Molecular weight
1209.4 g/mol
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~95% (subcutaneous injection)
CAS number
74381-53-6

Protocols

Dosing compared

Gonadorelin (GnRH)

Subcutaneous

  • 100 mcgSingle dose · One-time diagnostic testFDA-labeled gonadotropin (LH/FSH) stimulation test for pituitary reserve; 100 mcg given once subcutaneously (or IV), with LH measured at 0, 15, 30, 45, 60 and 120 minutes (Factrel) [4].

Intravenous

  • 5 mcg per pulse (range 1-20 mcg)Every 90 minutes via pulsatile pump · One or more ovulatory cycles; reassessed at 21-day intervalsFDA-labeled pulsatile regimen for ovulation induction in hypothalamic amenorrhea (Lutrepulse); intravenous pulsatile delivery gave better results than subcutaneous [5]. The 2-4 minute half-life makes pulsatile delivery essential.

Leuprolide

Subcutaneous

  • 1 mgOnce daily · OngoingThe original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].

Intramuscular

  • 7.5 mgEvery month · OngoingThe 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
  • 22.5 mgEvery 3 months · OngoingThe 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
  • 30-45 mgEvery 4-6 months · OngoingThe longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].

Applications

Best suited for

Gonadorelin (GnRH)

Improving fertility and conception chances
Gonadorelin (GnRH) is particularly well-suited for individuals focused on improving fertility and conception chances. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Regulating irregular menstrual cycles
Gonadorelin (GnRH) is particularly well-suited for individuals focused on regulating irregular menstrual cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhancing reproductive hormone levels
Gonadorelin (GnRH) is particularly well-suited for individuals focused on enhancing reproductive hormone levels. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting natural pregnancy attempts
Gonadorelin (GnRH) is particularly well-suited for individuals focused on supporting natural pregnancy attempts. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Leuprolide

Managing advanced or metastatic prostate cancer
Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
Controlling severe endometriosis pain
Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Treating symptomatic uterine fibroids
Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Delaying early puberty in children
Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].

Safety profile

Side effects

Gonadorelin (GnRH)

Common

  • Mild headache
  • Local injection site reactions (redness, swelling)
  • Temporary hot flashes
  • Mood changes or emotional sensitivity
  • Nausea or mild stomach upset
  • Allergic skin reactions
  • Dizziness or lightheadedness
  • Temporary changes in vision
  • Joint or muscle aches
  • Insomnia or sleep disturbances
  • Severe allergic reactions (difficulty breathing, swelling)
  • Severe hormonal imbalance symptoms
  • Ovarian hyperstimulation syndrome (OHSS)
  • Signs of blood clots (chest pain, leg swelling)
  • Severe mood changes or depression

Serious

  • Severe allergic reaction

Leuprolide

Common

  • Hot flashes (very common in men)
  • Decreased libido and erectile dysfunction
  • Injection site pain or swelling
  • Nausea
  • Fatigue
  • Mood changes or depression
  • Joint or muscle pain
  • Headaches
  • Dizziness
  • Thinning hair
  • Decreased bone density (osteoporosis with long-term use)
  • QT prolongation (rare but serious cardiac effect)
  • Tumor flare (temporary worsening of cancer symptoms in first weeks)
  • Severe allergic reactions
  • Spinal cord compression risk in men with metastatic disease

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Gonadorelin (GnRH)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Previously FDA approved: FACTREL (1982) as a diagnostic test of pituitary gonadotropin reserve and LUTREPULSE (1989) for ovulation induction. Both human products are discontinued in the US.
Safety overview
Gonadorelin is native GnRH and carries the safety profile established over 40+ years of clinical use in reproductive endocrinology. As the body's natural hormone, it produces minimal local side effects when dosed appropriately. The critical safety concern with gonadorelin is the initial flare effect within 24-48 hours of first dose—temporary elevation in FSH and LH—which can paradoxically suppress sex hormones before the desired stimulation occurs. This flare makes gonadorelin unsuitable for some conditions and explains why synthetic analogs (agonists, antagonists) are preferred in many modern fertility protocols.

Contraindications

  • Pregnancy or breastfeeding
  • Hormone-sensitive cancers (breast, prostate, ovarian)
  • Severe pituitary or hypothalamic disease
  • Undiagnosed abnormal vaginal bleeding
  • Known hypersensitivity to GnRH

Leuprolide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]

Contraindications

  • Pregnancy (may cause fetal harm) [6]
  • Undiagnosed vaginal bleeding [6]
  • Allergy to GnRH agonists or components [5][6]

Decision guide

Which is right for you?

Gonadorelin (GnRH)

Choose Gonadorelin (GnRH) if…

  • Improving fertility and conception chances
  • Regulating irregular menstrual cycles
  • Enhancing reproductive hormone levels
  • Supporting natural pregnancy attempts

Leuprolide

Choose Leuprolide if…

  • Managing advanced or metastatic prostate cancer
  • Controlling severe endometriosis pain
  • Treating symptomatic uterine fibroids
  • Delaying early puberty in children